Eftozanermin alfa

CAT: 0804-HY-P99934-01Size: 1 mgDry Ice: YesHazardous: No
CAT#:0804-HY-P99934-01Size:1 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Eftozanermin alfa (ABBV-621) is a tumor necrosis factor-related apoptosis-inducing ligand receptor (TRAIL-R) agonist. Eftozanermin alfa is a fusion protein consisting of a mutant immunoglobulin G1-Fc linked to 2 single-chain trimers of TRAIL. Eftozanermin alfa induces apoptosis in tumor cells by activation of death receptors (DR4 receptor and DR5 receptor) with Kds of 780 nM and 635 nM. Eftozanermin alfa can be used for the research of multiple solid and heme malignancies[1][2][3].
CAS Number
[1820660-69-2]
Product Name Alternative
ABBV-621
UNSPSC
12352203
Target
Apoptosis; Caspase; TNF Receptor
Type
Inhibitory Antibodies
Related Pathways
Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/eftozanermin-alfa.html
Purity
98.86
Solubility
H2O
Smiles
[Eftozanerminalfa]
Molecular Weight
(167.52 kDa)
References & Citations
[1]Tahir SK, et al. Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia. Blood. 2023 Jan 30:blood.2022017333.|[2]Silva A S, et al. Ex Vivo Drug Sensitivity and Functional Genomics Platform Identifies Novel Combinations Targeting Intrinsic and Extrinsic Apoptotic Signaling Pathways in Multiple Myeloma. Blood, 2020, 136 (Supplement 1) :49-50.|[3]Phillips DC, et al. Hexavalent TRAIL Fusion Protein Eftozanermin Alfa Optimally Clusters Apoptosis-Inducing TRAIL Receptors to Induce On-Target Antitumor Activity in Solid Tumors. Cancer Res. 2021 Jun 15;81 (12) :3402-3414.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 1
Isoform
Caspase 3; Caspase 7; Caspase 8

Popular Products